227 related articles for article (PubMed ID: 26961182)
1. The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.
Yapp DT; Wong MQ; Kyle AH; Valdez SM; Tso J; Yung A; Kozlowski P; Owen DA; Buczkowski AK; Chung SW; Scudamore CH; Minchinton AI; Ng SS
Angiogenesis; 2016 Apr; 19(2):229-44. PubMed ID: 26961182
[TBL] [Abstract][Full Text] [Related]
2. Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma.
Cham KK; Baker JH; Takhar KS; Flexman JA; Wong MQ; Owen DA; Yung A; Kozlowski P; Reinsberg SA; Chu EM; Chang CW; Buczkowski AK; Chung SW; Scudamore CH; Minchinton AI; Yapp DT; Ng SS
Br J Cancer; 2010 Jun; 103(1):52-60. PubMed ID: 20531411
[TBL] [Abstract][Full Text] [Related]
3. Monitoring the effects of anti-angiogenesis on the radiation sensitivity of pancreatic cancer xenografts using dynamic contrast-enhanced computed tomography.
Cao N; Cao M; Chin-Sinex H; Mendonca M; Ko SC; Stantz KM
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):412-8. PubMed ID: 24411612
[TBL] [Abstract][Full Text] [Related]
4. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
[TBL] [Abstract][Full Text] [Related]
5. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model.
Zhang X; Galardi E; Duquette M; Lawler J; Parangi S
Clin Cancer Res; 2005 Aug; 11(15):5622-30. PubMed ID: 16061881
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy.
Ciccolini J; Barbolosi D; Meille C; Lombard A; Serdjebi C; Giacometti S; Padovani L; Pasquier E; André N
Cancer Res; 2017 Sep; 77(17):4723-4733. PubMed ID: 28655786
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
10. Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.
Hasnis E; Alishekevitz D; Gingis-Veltski S; Bril R; Fremder E; Voloshin T; Raviv Z; Karban A; Shaked Y
Neoplasia; 2014 Jun; 16(6):501-10. PubMed ID: 24957319
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
[TBL] [Abstract][Full Text] [Related]
12. Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1.
Bocci G; Fioravanti A; Orlandi P; Di Desidero T; Natale G; Fanelli G; Viacava P; Naccarato AG; Francia G; Danesi R
Neoplasia; 2012 Sep; 14(9):833-45. PubMed ID: 23019415
[TBL] [Abstract][Full Text] [Related]
13. Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET.
Hernández-Agudo E; Mondejar T; Soto-Montenegro ML; Megías D; Mouron S; Sanchez J; Hidalgo M; Lopez-Casas PP; Mulero F; Desco M; Quintela-Fandino M
Mol Oncol; 2016 May; 10(5):704-18. PubMed ID: 26778791
[TBL] [Abstract][Full Text] [Related]
14. Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.
Vives M; Ginestà MM; Gracova K; Graupera M; Casanovas O; Capellà G; Serrano T; Laquente B; Viñals F
Int J Cancer; 2013 Nov; 133(10):2464-72. PubMed ID: 23649709
[TBL] [Abstract][Full Text] [Related]
15. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.
Tran Cao HS; Bouvet M; Kaushal S; Keleman A; Romney E; Kim G; Fruehauf J; Imagawa DK; Hoffman RM; Katz MH
Mol Cancer Ther; 2010 Jul; 9(7):2068-78. PubMed ID: 20606044
[TBL] [Abstract][Full Text] [Related]
16. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.
Francia G; Shaked Y; Hashimoto K; Sun J; Yin M; Cesta C; Xu P; Man S; Hackl C; Stewart J; Uhlik M; Dantzig AH; Foster FS; Kerbel RS
Mol Cancer Ther; 2012 Mar; 11(3):680-9. PubMed ID: 22188817
[TBL] [Abstract][Full Text] [Related]
17. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.
Raykov Z; Grekova SP; Bour G; Lehn JM; Giese NA; Nicolau C; Aprahamian M
Int J Cancer; 2014 Jun; 134(11):2572-82. PubMed ID: 24214898
[TBL] [Abstract][Full Text] [Related]
18. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Baker CH; Solorzano CC; Fidler IJ
Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
[TBL] [Abstract][Full Text] [Related]
19. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer.
Bruns CJ; Koehl GE; Guba M; Yezhelyev M; Steinbauer M; Seeliger H; Schwend A; Hoehn A; Jauch KW; Geissler EK
Clin Cancer Res; 2004 Mar; 10(6):2109-19. PubMed ID: 15041732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
